<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141392">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02111083</url>
  </required_header>
  <id_info>
    <org_study_id>15418</org_study_id>
    <secondary_id>F3Z-EW-IOQM</secondary_id>
    <nct_id>NCT02111083</nct_id>
  </id_info>
  <brief_title>A Study of 2 Different Forms of Insulin Lispro in Healthy Participants</brief_title>
  <official_title>Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Singapore: Health Sciences Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study involves 4 injections of insulin and its purpose is to:

        -  Determine if 2 types of insulin lispro are treated by the body in a similar way.

        -  Compare how the 2 types of insulin lispro affect blood sugar level.

        -  Determine the safety of each insulin lispro and any side effects that might be
           associated with them when given to healthy participants.

      The study is expected to last up to approximately 9 weeks for each participant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Area Under the Serum Insulin Concentration versus Time Curve From Zero to Time of Return to Baseline (AUC0-tlast) for Insulin Lispro A versus Insulin Lispro B</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Insulin Concentration (Cmax) for Insulin Lispro A versus Insulin Lispro B</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Observed Serum Concentration (tmax) for Insulin Lispro A versus Insulin Lispro B.</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Glucose Infused (Gtot) for Insulin Lispro A versus Insulin Lispro B</measure>
    <time_frame>Day1, predose through 8 hours post dose in each period.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Glucose Infusion Rate (Rmax) for Insulin Lispro A versus Insulin Lispro B</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Glucose Infusion Rate (tRmax) for Insulin Lispro A versus Insulin Lispro B</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Insulin Lispro A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Lispro A administered subcutaneously (SC) once in two of four study periods. (Two doses total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Lispro B administered SC once in two of four study periods. (Two doses total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>LY275585 administered SC.</description>
    <arm_group_label>Insulin Lispro A</arm_group_label>
    <arm_group_label>Insulin Lispro B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are healthy males or females

          -  Body mass index (BMI) between 18.5 and 29.9 kilogram per meter squared (kg/m^2)

          -  Are nonsmokers

          -  Have normal blood pressure and pulse rate, a normal electrocardiogram (ECG), and
             clinical laboratory test results within normal reference range at screening.

        Exclusion Criteria:

          -  History of first-degree relatives known to have diabetes mellitus

          -  Evidence of significant active neuropsychiatric disease

          -  Evidence of an acute infection with fever or infectious disease

          -  Intend to use over-the-counter or prescription medication (apart from vitamin/mineral
             supplements, occasional paracetamol, or birth control methods).

          -  Have used systemic glucocorticoids within 3 months prior to entry into the study.

          -  Have donated blood of 1 unit or more within the last 3 months prior to study entry

          -  Excessive alcohol intake

          -  Have a fasting venous blood glucose (fasting blood glucose [FBG], plasma) &gt;6
             millimoles per liter (mmol/L) at screening

          -  Have positive hepatitis B surface antigen.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin LISPRO</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
